<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02026310</url>
  </required_header>
  <id_info>
    <org_study_id>yml2013</org_study_id>
    <nct_id>NCT02026310</nct_id>
  </id_info>
  <brief_title>Efficacy/Safety Study of Glimepiride to Type 2 Diabetes Patients Based on Metformin And Basal Insulin Treatment</brief_title>
  <official_title>Efficacy/Safety Study of Adding Glimepiride to Type 2 Diabetes Patients With Inadequate Glycemic Control Based on Combination With Metformin And Basal Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qifu Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      All the guidelines suggest that metformin as the basis of type 2 diabetes medication, and
      evidence is sufficient.At the same time the basal insulin injection once a day are more and
      more widely used in diabetes patients in China.

      This study aims to evaluate the efficacy and safety of adding glimepiride to type 2 diabetes
      patients with inadequate glycemic control with combined therapy of metformin and basal
      insulin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 weeks after treatment, HbA1c values' change compared with baseline</measure>
    <time_frame>24 weeks after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hypoglycemia events</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>glimepiride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>on the basis of metformin and glargine, the initial dose of glimepiride is 2 mg,qd (before breakfast), and adjust the dosage for fasting plasma glucose, dosage-adding indicator is the FPG≥7.2, maximum dose of glimepiride is 4 mg/d per day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin and glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>on the basis of Metformin and glargine,no glempiride addition. dose of glargine was adjust according to the FPG, with the target less than 7.2mmol/l</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glimepiride</intervention_name>
    <description>on the basis of metformin and glargine, glimepiride is added; with the maximun dose of glimepiride, if the targeted FPG is not reached, glargine dose will be increased.</description>
    <arm_group_label>glimepiride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glargine and metformin</intervention_name>
    <arm_group_label>glimepiride</arm_group_label>
    <arm_group_label>Metformin and glargine</arm_group_label>
    <other_name>lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Understand the whole test process, voluntary and signed informed consent form

          -  Men and women aged 35 to 70 years old

          -  20≤BMI&lt;35 Kg/m2

          -  Diagnosed with type 2 diabetes

          -  Undergoing metformin(Dose not less than 1000 mg/day)in combination with basal insulin
             injection once a day

          -  HbA1c7.0－11%

          -  Patients should be able to self blood glucose monitoring

        Exclusion Criteria:

          -  sulfonylureas,glinides,TZDs use within 3 months before the study

          -  Pregnant or lactating women

          -  A history of ketoacidosis

          -  Allergy to sulfonylureas or sulfa drug patients

          -  Apparent dysfunction of liver and kidney patients(ALT&gt;2 times upper normal limit,serum
             creatinine&gt;1.2 times upper normal limit)

          -  Poor blood pressure control(systolic pressure&gt;180mmHg or diastolic blood
             pressure&gt;110mmHg)

          -  heart disease,cardiac insufficiency,unstable angina pectoris,ECG indicates left
             ventricle hypertrophy,severe anemia(Hb&lt;9.0g/d1)

          -  Severe diabetic nerve complications(ulcer of lower limb,neurogenic bladder)

          -  BMI&lt;20 orBMI≥35kg/m2

          -  Alcohol or drug abuse ,or can't collaborate due to mental disorder

          -  Digestion and absorption function obstacle or Other endocrine disorders

          -  Other chronic diseases required long-term glucocorticoid treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Qifu, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>First Affiliated Hospital of Chongqing Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing,</city>
        <state>Chongqing</state>
        <zip>400016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J; China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med. 2010 Mar 25;362(12):1090-101. doi: 10.1056/NEJMoa0908292.</citation>
    <PMID>20335585</PMID>
  </reference>
  <reference>
    <citation>Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol. 2010;2010:476279. doi: 10.1155/2010/476279. Epub 2010 Apr 26. Review.</citation>
    <PMID>20445742</PMID>
  </reference>
  <reference>
    <citation>Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89. doi: 10.1056/NEJMoa0806470. Epub 2008 Sep 10.</citation>
    <PMID>18784090</PMID>
  </reference>
  <reference>
    <citation>Yki-Järvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkilä M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1999 Mar 2;130(5):389-96.</citation>
    <PMID>10068412</PMID>
  </reference>
  <reference>
    <citation>Overkamp D, Volk A, Maerker E, Heide PE, Wahl HG, Rett K, Häring HU. Acute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabetes Care. 2002 Nov;25(11):2065-73.</citation>
    <PMID>12401758</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2013</study_first_submitted>
  <study_first_submitted_qc>December 31, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2014</study_first_posted>
  <last_update_submitted>January 26, 2016</last_update_submitted>
  <last_update_submitted_qc>January 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Qifu Li</investigator_full_name>
    <investigator_title>Qifu Li, Chongqing Medical University</investigator_title>
  </responsible_party>
  <keyword>glimepiride</keyword>
  <keyword>metformin</keyword>
  <keyword>basal insulin</keyword>
  <keyword>Hemoglobin A, Glycosylated</keyword>
  <keyword>glucose fluctuation</keyword>
  <keyword>hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

